...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZHCLF
1
Jan 03, 2024 11:19AM
1
Jan 03, 2024 05:13PM
2
Jan 03, 2024 06:48PM
1
Jan 03, 2024 09:36PM
1
Jan 03, 2024 10:53PM
2
Jan 03, 2024 10:56PM
2
Jan 04, 2024 07:35AM
1
Jan 30, 2024 02:24PM
4
Jan 30, 2024 04:37PM
1
Jan 31, 2024 08:28AM
3
Feb 01, 2024 08:20AM
3
Feb 01, 2024 10:24AM
6
Feb 01, 2024 10:55AM
5
Feb 02, 2024 07:27AM
4
Feb 06, 2024 11:23AM
3
Feb 08, 2024 06:43AM
4
Feb 08, 2024 06:53AM

The response; of course...nothing to offer of anything to us minions!!!!

Thank you for your question, and I apologize for the delayed response. We are excited about the potential of ZEN-3694 to benefit patients across the multiple oncology indications currently under clinical investigation. As you are likely aware, many of the ongoing trials are investigator-led studies and/or are being performed in collaboration with other parties, meaning that Zenith is not solely responsible for managing these trials. As a result, I do not specific timelines for when we can expect clinical data to be publicly available from our ongoing trials. However, I want to assure you that as data becomes available publicly, we will do our best to communicate any significant findings of these trials with our stakeholders. 

Thank you for your patience. 

Best regards, 

Chris

8
Feb 11, 2024 07:57AM
Share
New Message
Please login to post a reply